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Abstract
Neurooncology anticancer drugs are no exception—their distribution and tissue interac-
tions follow the general rules of classical pharmacology. In an attempt to assist with the 
new therapeutic approaches to manage cancers involving the central nervous system, 
classical chemobiodynamic compartment and pharmacokinetic models are discussed 
and illustrated. In addition, strategies and approaches for penetrating the blood brain 
barrier (BBB) are reviewed and modeled. Finally, in support of classical pharmacology, 
a new anticancer agent in clinical trial for brain tumors is reviewed as an example of 
 clinical onco-neuropharmacology.
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1. Introduction
A basic assumption in cancer management is that all cancer cells must be killed or removed. 
When surgical and radiotherapies fail to achieve this goal, anticancer agents become the hope 
for control of the advanced disease.
Classically, when a drug is injected or orally administrated, ideally it is 100% absorbed and 
enters the systemic circulation and distributed into the various body compartments. The drug 
then develops equilibrium (distribution) between metabolism, storage, target tumors, nontu-
mor organs, and final elimination [1].
The various body components and physiological barriers, which a cancer chemotherapeutic 
agent encounters from the time of administration until reaching the target site—the tumor—
are depicted in Figure 1 [2, 3].
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
The intensity and duration of drug action at any one site depends upon absorption, distribu-
tion, affinity, excretion, and metabolism for the drug.
It is anticipated that the drug’s tumor selectively will be such that it is absorbed preferen-
tially, with relatively low toxicity to the host organs, such as bone marrow, liver, kidney, 
gastrointestinal tract, etc. In addition, the accumulation of drug in the tumor will depend 
upon lipid storage, metabolic activation, and elimination. The liver has a principal role in 
the metabolism of cancer chemotherapeutic agents, but the other organs such as bone mar-
row, liver, intestines, kidneys, and even brain also contain low levels of drug-metabolizing 
enzymes [1, 2].
Table 1 outlines the major types of biotransformation which anticancer drugs can be expected 
to undergo. These include oxidative, reductive, and conjugation reactions, which usually 
result in increased product polarity. The resulting product(s) are either activated or  detoxified 
metabolites of the parent drug. The conjugated reactions usually result in water-soluble 
 products, which are excreted via the biliary and urinary systems.
Figure 1. Drug distribution.
Oxidation reactions Reductive reactions Conjugation reactions
Aromatic hydroxylation
1. O−, N−, S−, De-alkylation
2. Alkyl chain oxidation
3. S-Oxidation
4. Oxidative deamination
1. Keto reduction
2. Nitro reduction
3. Azo bond cleavage
1. Glucuronides
2. Ethereal sulfates
3. Mercapturic acids
4. Amino acid conjugates
5. Acetylated aromatic amines
Table 1. Biotransformation of drugs [4].
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2. Cancer Cells Involving CNS
Cancer cells are the target of cancer chemotherapeutic agents, and the rate at which cancer 
cells interact with these agents is controlled by the hierarchy of molecular organization shown 
in Figure 2.
However, for tumor cells colonized in the brain and associated central nervous system 
 structures, drugs/chemicals have an “additional hurdle,” they must penetrate the blood 
brain barrier (BBB) before classical interactions and pharmacological principles can be 
applied. Evidence supports anticancer agents exerting their antitumor activities via cytotoxic, 
 cytostatic and/or initiating immunotherapeutic mechanisms of action resulting in cancer cell 
death. All the chemotherapeutics interfere/interact with pathways in the cellular organization 
(Figure 2), thus inhibiting the synthesis of cancer cell DNA, RNA, proteins, and initiating 
lymphocyte—cancer cell recognition.
Although chemotherapeutics have their initial interactions on the molecular levels, they must 
first reach their targets. Thus, the abilities of chemotherapeutic agents to reach and interact 
with their targets are controlled by the hierarchy of distribution (Figure 1) and disposition 
(Table 1). These responses or changes are then transmitted to the respective molecular and/or 
cellular levels of cells (Figure 2).
3. Clark’s correlates
In his classic work on general pharmacology, A.J. Clark divided the possible quantitative 
drug action(s) into five types [4]:
Relationship between:
(1) Time and the production of some quantitative response.
(2) Time and the incidence of some “all-or-none effect.”
Figure 2. Hierarchy of cellular components. Molecular organization of cells.
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(3) Concentration and time of appearance of a selected action.
(4) Concentration and amount of quantitative response.
(5) Concentration and incidence of all-or-none effects.
The first three classes of Clark’s correlates are expressions of kinetics and are the rate(s) of 
actions for drugs, while the last two classes summarize equilibrium conditions between drugs 
and their target sites. The reactivity of an agent with a molecular target in a biological system, is 
dependent upon the concentration of the “active therapeutic available” and often more impor-
tant, is the rate at which the active form of the drug finds its way to the therapeutic sites/targets.
The selection of an optimal drug source requires consideration of:
(1) The qualitative and quantitative nature of the drug’s known toxicity.
(2) The influence of drug concentration with time on tumor cell kill.
(3) The drug’s pharmacology.
Consideration is also required for recovery time for the target organ, as well as  nontarget 
organs, such as the bone marrow and gastrointestinal tract to recover prior to the 
 administration of additional drugs. This depends on the pharmacologic disposition of the 
drug, since  absorption, distribution, elimination, and metabolism affect the toxicity and 
 efficacy, which can be achieved in the treatment of cancer.
4. Pharmacokinetics
Since most aspects of pharmacology involve dynamic processes, it is necessary to consider the 
rates or time courses for this process [5]. Pharmacokinetics is the quantitative measurement 
of concentration vs. time for drug and metabolite(s) in respective biological fluids, tissues, 
and for excretion. Pharmacokinetics is not the measurement of a solution to a problem; it is 
merely the scientific analysis of a drug’s chemobiodynamics— the distribution of a drug in 
an organism [6].
Common questions in which applications of pharmacokinetics have proven to be useful 
include:
(1) How a drug is eliminated and how fast?
(2) What factors affect the rate of elimination?
(3) What is the optimal drug regimen for a drug?
(4) How can drugs and radiotherapy be combined?
(5) Is the pharmacological response due to the parent drug or a metabolite?
(6) Does drug distribution change with multiple dosing?
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(7) How do the pharmacokinetics of chemically related drugs compare?
(8) How are the pharmacokinetics of a drug altered by the simultaneous administration of a 
second drug or radiation?
The initial step in a pharmacokinetic study is to determine if a drug is distributed by first or 
second-order reactions. The second step is to develop models for documentation.
4.1. First Order Kinetic Reactions
First-order reactions usually produce parallel curves for different doses of a drug with 
 proportional shifts in the ordinate. If not, one must determine, which saturation processes or 
enzymatic reactions or zero order reactions are present.
Once the reaction kinetics is found to be first order, a model must be formulated. Models are 
based on the concepts of compartments. The simplest first order pharmacokinetics normally 
fits a one compartment model; for example, a drug is administered by intravenous injection 
and eliminated only in the urine or some other single route.
The rate of disappearance of the drug from the blood is proportional to the actual  concentration 
of drug (x) in the blood (Figure 3).
Figure 3. Pharmacokinetics of a one-compartment system.
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Plotting the log [x] vs. time produces a slope equal to: −k/2.303.
The half-life (t1/2) of the drug (x) is the time in which the concentration in the primary compart-ment decreases by 50%:
  t 
1/2  = 0.693/k 
The half-life is only meaningful as long as there is a one compartment model and the reaction 
is first-order. The half-life is also related to the clearance (Cl) and distribution (V
d
) of the drug:
   t 1/2 =  0.693  V d  /Cl, where Cl = k ×  V d  
and
  
 V 
d =
  dose/  x 
0
  ;  x 
0
 is obtained by extrapolating the curve to t = 0.
      
Also  −  t 
1/2  = 06.93/k = 0.693  V d  /Cl, where : Cl = k  V d and  V d  = dose /  x 0 . 
Thus, the elimination is calculated as – dx/dt = −kx (with k = elimination constant)
4.2. Second Order Kinetic Reactions
Second-order reactions are best described in models where there are both elimination and dis-
tribution to other compartments and the curve would look like Figure 4. The upper portion 
of the curve represents distribution, while the lower flatter portion represents elimination [7].
The slope of the elimination phase or β is calculated by extending or extrapolating the lower 
portion of the curve to the ordinate (intercept) at B. The slope of the distribution phase or α 
is calculated by taking the differences between times for actual curve A and extrapolating to 
(B) back to T
0
.
Figure 4. Pharmacokinetics of a two-compartment system [2].
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Here, t1/2 (α) = 0.693/α and t1/2 (β) = 0.693/β – Figure 4.
There are some disadvantages to this type of feathering—data can be biased when converting 
from linear to log scale and objectivity lost (too much importance placed on the terminal part of 
the curve where there is often least confidence). Computer models are best employed, if possible.
In this type of example, it is meaningless to speak of T1/2, since the whole curve is determined 
by two T1/2 values analogous to K1 and K2, and one cannot combine these two values directly. 
It is no longer true that the T1/2 values remain constant for greater than two compartments.
4.3. Drug Distribution
Another reason for the success or failure in drug activity is related to the pharmacologic dis-
position of drugs in subjects. Even if the tumor is sensitive to a drug, the latter is not useful 
unless it reaches the tumor site and remains there in cytotoxic (therapeutic) concentrations 
long enough to kill the tumor cells. In general, the purpose of pharmacology studies is to 
inform the treating physicians what is an effective concentration (C) of the drug that can be 
administered by a certain route and be present (available) for a sufficient period of time (T) to 
bring about the desired effect. This is referred to as the “optimal C × T,” and in most diseases, 
this can be approximated for dosing in humans through preclinical studies in animal models. 
Generally, 10% of the LD
10
 in mice is the acceptable starting dose [1].
4.4. Correlation of Pharmacokinetic Profile
What makes cancer different from other diseases is the need to relate optimal C × T to the 
phases of the cell cycle [1]. First, the optimal C × T for the tumor must be estimated for the 
real target—the tumor cells that are susceptible to be killed by the drug. Second, calculations 
are required to define the optimal C × T for human safety (e.g., the C × T that will be toler-
ated by normal organ tissues (bone marrow or gastrointestinal tract in most cases). Third, 
the cell population kinetics of both tumor cells and normal cells will be perturbed as a result 
of the drug’s administration; however, the cancer cell growth fraction should be reduced to 
a greater degree, with sparing of normal tissues. Thus, the potential for drug’s usefulness is 
a balance between anticancer activity and damage to healthy organs/tissues. Understanding 
the failure of active drugs to cause regression of cancer will depend to a significant extent 
upon successful delineation of this complex pharmacology.
Thus, the effectiveness of an antitumor agent is directly related to C × T, which is markedly 
affected by dose, schedule, and its pharmacokinetics discussed above. The sensitivities of the 
cancer cells, as well as, normal tissue to drugs are the variable factors, which determine the 
potential usefulness of a drug. Documentation of the optimal C × T is usually conducted in 
Phase I studies and will relate clinical responses to acceptable doses and schedules necessary 
to standardize drug use in humans.
  The optimum C × T should kill the maximum tumor  
cells with minimum lethality to cells of normal tissue. 
The C × T product is also known as the area under the curve (AUC) and discussed and illus-
trated latter in this chapter.
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5. Blood brain barrier
The chemobiodynamic relationship of a drug with the blood brain barrier (BBB) evaluated 
using in vivo, in vitro, and in silico (computational) models in attempt to appreciate the best 
design for novel anticancer agents to be used in subjects with malignant tumors involving the 
brain and central nervous system.
The blood brain barrier was discovered over 100 years ago by Paul Ehrlich who found that 
water soluble dyes stained all organs of animals except for their brains and central nervous 
system (CNS) [8]. Subsequently, other researchers found that Ehrlich’s dye injected into the 
brain did not enter the blood stream and hence a barrier existed between the two compart-
ments. These compartments could be traversed by more lipophilic substances however [9]. In 
general, more lipid soluble drugs can traverse the blood brain barrier by passive diffusion, 
while other molecules can cross the blood brain barrier (BBB) by active transport by proteins 
such as P-glycoprotein (P-gp) [10].
The BBB differs from normal capillaries in that it has tight junctions in the endothelial 
cell walls with specialized pores and junctions (formed by terminal surfaces of endothelial 
cells, neurons, astrocytes, etc.) that allow selective transport through the openings. The 
BBB is also highly electrically resistant confirming that it is very fatty and free of aqueous 
electrolytes [5].
To treat cancers involving the CNS, the BBB is the protective “no man’s land” must be pen-
etrated by anticancer agents. Figure 5 depicts two modes of drug transport into the brain 
and intracerebral cancers. Figure 5(a) requires drug to penetrate via diffusion or a transfer 
pathway [12]. Figure 5(b) allows drugs to penetrate the CNS via the association with RBCs or 
transport through cancer-associated breaks in the BBB [11].
Figure 5a. Primary tumor mass involving the CNS. Drugs  can only penetrate the BBB by passive diffusion or active 
transport.
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5.1. Calculation of Log P
Measuring or calculating log P is the most important molecular attribute to defining lipophilic-
ity and the ability of the drug to diffuse across the lipophilic BBB. This is measured by dissolving 
the drug in octanol and then shaking with equal volumes of water. The concentration of drug is 
then measured in both phases and the ratio of octanol-water is calculated according to Eq. (1) [6].
  log  P 
octanol/water
  = log  ( [ solute ] octanol  /  [ solute ] water ) (1)
Since, very lipophilic compounds tend to be highly lipoprotein bound and associate/bind to 
lipid membranes, thus the ideal octanol-water partition coefficient for a neurotargeted drug 
(at pH 7.4) to diffuse from the serum into BBB into the CSF should be ≤ log P 5 [2, 12].
The estimation or determination of BBB permeability as log
BBB
 (the concentration of drug in 
the brain is divided by concentration in the blood) is accomplished as follows:
(1) In vitro kits to measure log
BBB
 in monkey or rat brain cells [13].
(2) In vivo during a clinical trial (Phase I).
(3) In silico computer models that simulate human BBB and are validated by correlating with 
drugs of known and measured log
BBB
 values [5]. For example, for DM-CHOC-PEN, temo-
zolomide and others, log P can be calculated from their structure and from Eq. (2) log
BBB
 
calculated [13–15].
  log 
BBB
  =   ( log P − 0 / 1725 )  / 2.808. (2)
Table 2 lists compounds with known brain and/or CNS activity and from their structure log 
P is calculated. From this value and Eq. (2) log
BBB
 is calculated; the latter is compared to litera-
ture values in Table 2. The calculated and literature values are in good agreement indicating 
that log P is a good predictor of passive diffusion through the BBB. However, one must realize 
Figure 5b. Breaks (leaks) in the BBB 2° to cancer cell  penetration and tumor growth allow RBCs  and associated 
drugs  easily penetration into tumors growing in the brain.
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Compound Structure Calculated log P Calculated log
BBB
Calculated BBB Actual BBB [15]
Cis-platinum −2.83 −1 0.09 0.05–1
Cytarabine −2.77 −1 0.1 1
Pentostatin −2.35 −0.9 0.13 0.1-0.13
Temozolamide −1.9 −0.7 0.18 0.19
Cladribine −0.38 −0.2 0.64 0.25
Dacarbazine −0.35 −0.19 0.69 0.14
Melphalan −0.01 −0.06 0.86 0.01–0.1
Busulfan 0.08 −0.03 0.9 1
Topotecan 1.41 0.44 2.76 0.42
Carmustine 1.67 0.5 3.44 2.3–9
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that this is just a predictor of drug penetration across the BBB. Some drugs have higher cyto-
toxicity and selectivity than others and as such are active at lower concentrations than other 
drugs, e.g., temozolomide. Other caveats include the fact that drugs that penetrate the BBB 
can be “pumped out” — P-glycoprotein (GgP), thus the log P is not predictive that all drugs 
will be active [10, 15].
6. Clinical applications
The above introductory information provides the general principles, which must be consid-
ered when designing or planning on using a drug to treat cancer involving the brain.
4-Demethyl-4-cholesteryoxycarbonylpenclomedine (DM-CHOC-PEN) [Figure 6] is a lipo-
philic cholesterol carbonate polychlorinated pyridine that is cytotoxic and penetrates the BBB, 
both because of its log
BBB
 (Table 2), as well as an affinity for red blood cells (RBCs) [16–18].
6.1. DM-CHOC-PEN PK Profile With Cell Cycle
DM-CHOC-PEN‘s PK profile is best modeled via a two compartment model with ~5% being 
excreted unchanged in the urine [17]. The use of plasma pharmacokinetics is of great impor-
tance in considering its use. The drug has produced excellent responses in primary cancers 
(glioblastomas) as well as metastatic (lung, melanoma, breast) cancers involving the CNS [18]. 
DM-CHOC-PEN is lipophilic and penetrates the BBB, as well as transported and activated in 
metastatic cancers involving the CNS through a 4-tier mechanism: (1) transport per RBCs into 
the brain via breaks in the BBB; (2) entry into cancer cells per the l-glutamine (GLM) transfer 
system; (3) activation to DM-PEN (active molecule) in situ in the acidic microenvironment 
of cancer cells; and (4) bis-alkylation of DNA at N7-guanine and N4-cytosine—with cellular 
death [11].
Compound Structure Calculated log P Calculated log
BBB
Calculated BBB Actual BBB [15]
Lomustine 2.96 1 10 >0.5
DM-PEN 4.32 1.5 30 TBD
DM-CHOC-PEN 9.68 3.4 2431 TBD
Table 2. Calculated and structure related activities for molecules with known intracerebral activity [15].
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It’s a large molecule and if there are liver metastases or other hepatic disease involving the 
liver there can be biliary congestion resulting in reversible jaundice [17].
The pharmacokinetics of DM-CHOC-PEN’s disappearance from plasma after a single intrave-
nous dose consist of an initial phase having a T1/2 of 5 hours and a final phase T1/2 of 245 hours 
(Figures 7 and 12). The slow, final phase of DM-CHOC-PEN elimination is the reason for the 
single high dose schedules that are currently being employed [18].
6.2. DM-CHOC-PEN Degradation
It has been found that the hydrolysis of DM-CHOC-PEN to DM-PEN (Figure 7) is the prin-
ciple route of degradation and elimination of the drug in animals and humans [16].
Results vary with individual patients but on a mass balance analysis 1–10% of DM-CHOC-
PEN are excreted unchanged and the metabolite, DM-PEN is excreted 10–100% in the urine. 
Figure 8 shows a pattern seen for 12 subjects treated once with 70–85.8 mg/m2 plasma and 
urine drug and metabolite levels [17].
6.3. Area under the curve
Increasing the dose of DM-CHOC-PEN increases the plasma concentration of drug and 
metabolites. The C
max
 increased with the dose giving rise to an increase in area under the 
curve (AUC) (Figure 9). Figures 9 and 10 combine and summarize the AUCs for DM-CHOC-
PEN vs. time [16, 17].
6.4. Distribution and elimination
DM-CHOC-PEN follows a standard two compartment model for elimination [17].
The preclinical and Phase I trial results suggest that the brain and central nervous system is 
targeted, but that all tissues including cancer tumors will absorb drug [17, 19]. So the second 
step in decreasing DM-CHOC-PEN blood levels is drug elimination. From bioavailability 
Figure 6. DM-CHOC-PEN and metabolite DMPEN.
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kinetic studies, this has found to be about 4%. The third step of elimination is after the meta-
bolic degradation to a more water soluble and excreted as DM-CHOC-PEN. For DM-CHOC-
PEN, the drug is primarily eliminated as DMPEN in the urine, which accounts for 57% of the 
dose on a mass balance basis. The metabolite on average has maximal plasma concentration 
14 hours after drug administration (Figure 8) [17, 19].
Figure 8. DM-CHOC-PEN + DM-PEN plasma and urine levels.
Figure 7. Plasma decay curve for DM-CHOC-PEN: 85.8 mg/m2 IV once.
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The whole point of the above discussion is to illustrate that there are differing kinetic pro-
cesses involved in drug elimination such that elimination is not linear with time. In clas-
sical pharmacokinetics, this is described as two compartment model and you know you 
have one when you plot Log Drug Plasma Concentration vs. time and you see two slopes 
(Figure 12).
Figure 10. Area under the curve (AUC) for DMCHOCPEN (decadron patients excluded) as a function of DMCHOCPEN 
dose.
Figure 9. AUC—1 subject–doses of 39 mg/m2, then 21 days later—55 mg/m2.
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Thus, from the DM-CHOC-PEN and DM-PEN study, the drug is eliminated in a two com-
partment model (see Figures 11 and 12). In addition, DM-CHOC-PEN has been identified in 
the CNS and tumors as DNA adducts [17, 19].
Figure 12. Elimination of DM-CHOC-PEN identified as two-compartment model as log plasma concentration vs. time is 
bi-linear two slopes evident initial α or distribution phase: terminal β or elimination phase.
Figure 11. Distribution of DM-CHOC-PEN into the CNS and Cancer Cells.
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7. Conclusion
An attempt to review neuropharmacology and distribution of anticancer agents in the central 
nervous system has been made. However, actually little is known about the interactions of 
drugs with the various levels of the CNS. We combined drugs in neurooncology but actually 
know little about the neuropharmacology of any single agent. In fact, Clark’s basic pharma-
cological questions that should have been answered for all the agents we use but have been 
answered in only a few cases. With the current interests in neurooncology, we may finally 
make some progress in the specialty—but let’s do it correctly.
Acknowledgements
Supported by NCI/SBIR grants – 5R44CA85021 and 3R43CA132257.
Author details
Andrew H. Rodgers* and Lee Roy Morgan
*Address all correspondence to: ahrodgers@gmail.com
DEKK-TECK, Inc. New Orleans, LA, USA
References
[1] Morgan, L.R., Principles of Pharmacology, Practical Oncology Today. Part II. Adra Labs, 
1977.
[2] Morgan, L.R. and Weatherall, T.J., “Pharmacology and drug distribution. In: Combined 
Modalities. Chemotherapy/Radiotherapy.” Phillips, T.L. (ed.) Int. J. Radit. Oncol., Biol. 
Phys., 17, 20–24,1974.
[3] Oliverio, V.T. and Guarino, A.M., “Absorption, protein binding, distribution, and excretion of 
antineoplastic drugs.” Biochem. Pharmacol. 23, Supp 2:9–20, 1974.
[4] Clarke, A.J., General Pharmacology, in A. Heffter (ed.), “Handbuch der experimentellen 
Pharmakologie,” vol. 4, Springer-Verlag, Berlin, 1937, pp. 63–65.
[5] Goodman & Gilman’s The Pharmacological Basis of Therapeutics, edition 11, Brunton, 
LL, Lazo, JS, Parker, KL, McGraw-Hill, New York, 2006,.
[6] Schuler, F.W., Chemobiodynamics and Drug Design, McGraw-Hill Book Co. New York, 1960.
[7] Germain, R., Bastian, G., Serota, D., Struck, R.F., Morgan, L.R., Isophosphoramide mus-
tard (IPM): preclinical pharmacology and toxicology in rodents, dogs and primates. 
Cancer Chemother. Pharmacol., 51, 1204–1212, 2004.
New Approaches to the Management of Primary and Secondary CNS Tumors18
[8] Ehrlich, P., Das Sauerstoff-Bedurfniss des Organismus. Eine farbenanalytische Studie. 
Verlag von August Hischwald 1–167, 1885.
[9] The Davis Lab. History of the Blood Brain Barrier, University of Arizona, Tucson, AZ 
85721, 2014.
[10] Hartz, A.M.S. and Bauer, B., Regulation of ABC transporters at the blood brain barrier: 
new targets for CNS therapy. Mol. Interv., 10(5), 293–304, 2010.
[11] Morgan, L.R., Benes, E., Rodgers, A.H., Mahmood, T., Weiner, R.S., Cosgriff, T.S., 
Influence of L-Glutamine on DM-CHOC-PEN Activity in NSLC, 16th Int.Lung Cancer 
Congress, 2015.
[12] Carpenter, T.S., Kirshner, D.A., Lau, E.Y., Wong, S.E., Nilmeier, J.P., Lightstone, F.C., 
A method to predict blood brain barrier permeability of drug like compounds using 
molecular dynamic simulations. Index of compounds with data indicating they either 
cross or do not cross the BBB (or are found in CSF). Biophys. J., 107, 630–641, 2014.
[13] http://www.pharmacocell.co.jp/en/bbb/index_e.html
[14] http://www.molinspiration.com
[15] http://www.brynmawr.edu/chemistry/Chem/mnerzsto/bbb_index_of_compound-opti-
mized.pdf
[16] Morgan, L.R., Struck, R.F., Rodgers, A.H., Jursic, B.S. Waud, W.R., Carbonate and car-
bamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer 
Chemother. Pharmacol., 64, 829–835, 2009.
[17] Weiner, R.S., Ware, M.L., Bastian, G., Rodgers, A.H., Urien, S., Morgan, L.R., Comparative 
pharmacokinetics of 4-demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-
PEN) in humans, Proc. Amer. Assoc. Cancer Res., 53, 758, 2012.
[18] Weiner, R.S., Friedlander, P., Gordon, C., Saenger, Y., Ware, R.L., Mahmood, T., Rodgers, 
A.H., Bastian, G., Urien, S., Morgan, L.R., Early clinical trial for 4-demethyl-4-choles-
teryl-oxycarbonylpenclomedine (DM-CHOC-PEN) in patients with advanced cancer. 
Proc. Am. Assoc. Cancer Res., 56, 246, 2015.
[19] Morgan, L.R., Rodgers, A.H., Bastian, G., Benes, E., Waud, W.S., Papagiannis, C., 
Krietlow, D., Jursic, B.S., Struck, R.F., LaHoste, G., Thornton, M., Luttrell, M., Stevens, E., 
Thompson, R., Comparative preclinical pharmacology and toxicology for 4-demethyl-
4-cholestryloxylcarbonylpenclomedine (DM-CHOC-PEN) – a potential neuro-alkylat-
ing agent for glioblastoma (GBM) and metastatic cancers involving the central nervous 
system. In: Morgan, LR (ed.): Tumors of the Central Nervous System – Primary and 
Secondary, Rijeka, InTech; 2014, pp. 239–263.
NeuroPharmacology: As Applied to Designing New Chemotherapeutic Agents
http://dx.doi.org/10.5772/67591
19

